Universal flu vaccine enters first human trial
NCT ID NCT06460064
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new universal influenza vaccine called fH1/DSP-0546LP in 144 healthy adults aged 18 to 40. The goal was to check safety and how well the vaccine triggers an immune response. Participants received two shots three weeks apart, with different doses or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fH1/DSP-0546LP (universal influenza vaccine)
What this could lead to
If it works, this could lead to a vaccine that protects against many flu strains, reducing the need for yearly shots.
What could go wrong
This is a very early Phase 1 trial with only 144 healthy adults, so safety and immune response are still unproven. The vaccine may not work in larger, more diverse populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Vaccinology
Ghent, Corneel Heymanslaan 10, 9000, Belgium